Oval Medical representatives Matthew Young (CTO), Pete Evans (Dir. Device Development) and Bastiaan de Leeuw (Dir. Business Development) will attend Pharmapack Europe (Paris, 10-11 Feb 2016). Our autoinjector products will be on display at booth #537 of our Japanese partner company Solize. If you would like to set up an appointment with one of us, […]
Barbara Lead (CEO) and Matthew Young (CTO) will be present at Biotech Showcase 2016 from Jan 11th-13th (https://lnkd.in/e7-gUTh) in San Francisco. To arrange to meet them you can contact us via our Contact page.
SyndicateRoom, a crowdfunding platform that invested in Oval Medical, has just released a video in which CEO Ms. Barbara Lead presents the current development progress at Oval Medical since August 2014.
Oval Medical’s CEO, Ms Barbara Lead will be one of the panellists in the Industry Roundtable “Drugs, Delivery, and Patients – How Will We Bring It All Together in the New World?” at the Annual Meeting of the Controlled Release Society on Sunday July 26th. The panel discussion, moderated by Ms Debra Bingham (Partner at […]
Oval Medical Technologies is pleased to announce the appointment of Dr Jim Millen to the Oval board. Jim is a physician with over 15 years’ experience in life science companies including Allergan and GSK. He has a track record of leading substantial commercial deals in pharma and biotech and brings this strength to the board […]
Oval Medical’s partner Solize Corporation will exhibit and present at the InnoPack 2015 conference in Tokyo (April 22-24th) in conjunction with the CPhI event held at TokyoBigSight. Representatives from Oval and Solize will be present to demonstrate the Oval autoinjectors and collaboration opportunities. Oval Medical has been attending and exhibiting at a number of conferences […]
April 2015 Oval Medical completes Innovate UK (formerly The Technology Strategy Board) Smart Award Grant for development of manufacturing equipment for their novel container closure system. Oval Medical has developed bespoke sealing equipment for the drug container in collaboration with 3P Limited; this is a key manufacturing step for its leading edge auto injector. Commenting […]
March 2015 Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times. This equipment will form part of the manufacturing process for clinical […]
January 2015 Oval is pleased to announce that Desmond Astley-Cooper of Turquoise Associates International joined the board in December 2014 as the representative of the Low Carbon Investment Fund (LCIF)
November 2014 Oval Medical received £25,000 to contribute to market research for its new, innovative epinephrine autoinjector for the treatment of anaphylactic shock. The incidence of allergies that can cause this serious and potentially fatal reaction is growing worldwide. Oval’s epinephrine autoinjector incorporates the same design philosophy as the first device being used for sumatriptan. […]